- Home
- IBTA vs EBS Comparison
IBTA vs EBS Comparison
Compare IBTA & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | EBS |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 605.8M | 625.0M |
| IPO Year | 2024 | 2006 |
Fundamental Metrics
Financial Performance| Metric | IBTA | EBS |
|---|---|---|
| Price | $21.46 | $11.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $37.38 | $15.00 |
| AVG Volume (30 Days) | 465.4K | ★ 832.0K |
| Earning Date | 11-12-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 395.09 | N/A |
| EPS | ★ 2.40 | 1.35 |
| Revenue | $352,243,000.00 | ★ $788,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.21 |
| P/E Ratio | $8.91 | ★ $8.45 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.40 | $4.02 |
| 52 Week High | $76.00 | $13.41 |
Technical Indicators
Market Signals| Indicator | IBTA | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 56.26 |
| Support Level | $22.19 | $11.17 |
| Resistance Level | $24.40 | $12.28 |
| Average True Range (ATR) | 0.88 | 0.48 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 2.56 | 63.25 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc.
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.